Breakfast breakthrough? study tests if food can improve kidney cancer drug tolerability
NCT ID NCT05263245
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at whether taking the kidney cancer drug cabozantinib with a light breakfast changes how much drug gets into the body. Twelve patients with advanced kidney cancer took the drug both on an empty stomach and with a light breakfast, and researchers measured drug levels in their blood. The goal is to see if eating a light breakfast could allow patients to skip doses occasionally, potentially reducing side effects and costs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cabozantinib
What this could lead to
If it works, this could lead to a more convenient dosing schedule for cabozantinib, potentially reducing side effects and treatment costs.
What could go wrong
This is a small, early-phase study with only 12 participants, so results may not apply broadly. The main goal is measuring drug levels, not proving better outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Erasmus Medical Center
Rotterdam, South Holland, 3015 GD, Netherlands
-
Leids Universitair Medisch Centrum
Leiden, South Holland, 2333 ZA, Netherlands